Drug Approval | April 18, 2022
Zydus Lifesciences receives final approval from USFDA for Cyanocobalamin Injection
The drug will be manufactured at the group's injectables manufacturing facility at Jarod, Gujarat
The drug will be manufactured at the group's injectables manufacturing facility at Jarod, Gujarat
This product is indicated for the short-term treatment of a breathing problem (apnea) in premature infants
The drug is indicated for use in combination with other drugs
It is only the second generic application approved by the USFDA
Nulibry is approved by the U.S. Food and Drug Administration (USFDA) to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening paediatric genetic disorder
OxemiaTM (Desidustat) is an oral tablet formulation that is the first-in-India alternative to injectable erythropoietin-stimulating agents (ESAs)
Zydus unveils its ‘innovation and care’ centric corporate brand identity
The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad
The vaccine will be priced at Rs. 265 per dose and the applicator being offered at Rs. 93 per dose excluding GST
Subscribe To Our Newsletter & Stay Updated
